Subscribe

Reirradiation of Pelvic Area Is Safe and Improves Quality of Life

Urology Practice Management - April 2016, Vol 5, No 2 - Genitourinary Cancers
Phoebe Starr

Experience at a high-volume cancer center suggests that nonstereotactic body radiotherapy external beam reirradiation of the pelvis for cancer recurrence or for a second genitourinary malignancy is safe in patients with advanced cancer, and can achieve excellent and durable palliation of symptoms without severe radiation-induced morbidity. These patients are typically near the end of life, and palliation of their symptoms improves the quality of their remaining life.

Reirradiation of the genitourinary area with external beam radiation is debatable, with no existing guidelines, said lead investigator Sophia C. Kamran, MD, Harvard Radiation Oncology Program, Boston, at the 2016 Genitourinary Cancers Symposium. She reported the results of a retrospective review of 28 patients with locally advanced symptomatic disease (27 males, 1 female) who were reirradiated.

“Patients with genitourinary malignancies commonly receive radiation. Many may develop a recurrence or a secondary neoplasm. The cancer community may have concerns about the risk of bowel and bladder toxicity with external beam reirradiation of the pelvis. We showed that with careful planning, we can safely reirradiate the pelvic area and eliminate toxicity,” Dr Kamran said.

Study Details

Patients had a variety of primary tumor types, including rectal, bladder, penile, prostate, ureteral, and large-cell lymphoma. For their primary disease, the patients were treated with radiation alone (47%), chemotherapy plus radiation (7%), radiation plus surgery (32%), or all 3 modalities (14%).

The patients were retreated with high-dose external beam pelvic reirradiation, defined as >50 Gy given with standard fractionation or hypofractionation that is bioequivalent to ≥50 Gy.

All patients had pain, bleeding, and/or bladder symptoms as indications for reirradiation. Effectiveness was scored according to reduction in these signs and symptoms. The treatment was carefully planned to increase precision and to avoid affecting critical normal organs using a variety of maneuvers depending on the case, including 4-dimensional simulation (N = 7), customized immobilization devices (N = 28), image-guided radiation delivery (N = 20), 3-dimensional conformal therapy (N = 20), and 2-dimensional therapy (N = 4).

The median overall survival was 5.8 months (range, 0.3-39 months), and death was secondary to systemic disease in all cases.

Excellent and durable palliation was observed after reirradiation. “Ninety-two percent of patients responded to reirradiation at high doses with resolution of their symptoms and limited toxicity,” Dr Kamran said.

No Radiation Therapy Oncology Group grade 3 or 4 treatment-related toxicity was reported.

“Many people assume this is not safe. We monitored patients’ symptoms weekly. Reirradiation provides great palliative therapy in patients with a recurrence or a new second cancer. They can enjoy good quality of life free of these symptoms near the end of life,” she stated.

“Meticulous treatment planning, with avoidance of sensitive structures, and short survival times may have contributed to the low morbidity we saw in this series. These results need to be validated in a prospective study with a larger number of patients,” Dr Kamran concluded.

Related Items
Shorter Hypofractionated Therapy New Standard for Prostate Cancer
Phoebe Starr
Urology Practice Management - October 2016, Vol 5, No 5 published on October 10, 2016 in Prostate Cancer
Adjuvant Chemoradiotherapy May Provide Benefit in Locally Advanced Bladder Cancer
Phoebe Starr
Urology Practice Management - June 2016, Vol 5, No 3 published on June 20, 2016 in Bladder Cancer
Atezolizumab, a PD-L1 Inhibitor, Shows Impressive Results in Metastatic Urothelial Bladder Cancer
Charles Bankhead
Urology Practice Management - April 2016, Vol 5, No 2 published on May 4, 2016 in Genitourinary Cancers
Real-World Data Show 2-Year Survival Predicts Long-Term Survival for Metastatic Germ-Cell Testicular Cancer
Phoebe Starr
Urology Practice Management - April 2016, Vol 5, No 2 published on May 4, 2016 in Genitourinary Cancers
Regular Aspirin Use Reduces the Risk for Death from Prostate Cancer
Phoebe Starr
Urology Practice Management - February 2016, Vol 5, No 1 published on February 19, 2016 in Prostate Cancer
Liquid Biopsy Characterizing Circulating Tumor Cells Can Aid Treatment Selection
Phoebe Starr
Urology Practice Management - February 2016, Vol 5, No 1 published on February 19, 2016 in Prostate Cancer
Genomic Test Supports Treatment Decisions in Prostate Cancer
Phoebe Starr
Urology Practice Management - December 2015, Vol 4, No 6 published on December 28, 2015 in Prostate Cancer
Docetaxel Boosts Survival in Patients with Hormone-Naïve Metastatic Prostate Cancer
Phoebe Starr
Urology Practice Management - August 2015, Vol 4, No 4 published on August 17, 2015 in Prostate Cancer
History of Testicular Cancer Increases Risk for Aggressive Prostate Cancer Later On
Phoebe Starr
Urology Practice Management - April 2015, Vol 4, No 2 published on April 14, 2015 in Genitourinary Cancers Symposium
AR-V7 Predicts Chemotherapy Sensitivity in Metastatic Prostate Cancer
Phoebe Starr
Urology Practice Management - April 2015, Vol 4, No 2 published on April 14, 2015 in Genitourinary Cancers Symposium
Last modified: May 11, 2016
  • American Health and Drug Benefits
  • Association for Value Based Cancer Care
  • Lynx CME
  • Oncology Practice Management
  • Rheumatology Practice Management

Search